Version 1
: Received: 30 January 2024 / Approved: 30 January 2024 / Online: 31 January 2024 (10:41:59 CET)
Version 2
: Received: 2 March 2024 / Approved: 3 March 2024 / Online: 4 March 2024 (09:56:14 CET)
Soares, É.N.; Costa, A.C.S.; Ferrolho, G.J.; Ureshino, R.P.; Getachew, B.; Costa, S.L.; da Silva, V.D.A.; Tizabi, Y. Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease. Cells2024, 13, 474.
Soares, É.N.; Costa, A.C.S.; Ferrolho, G.J.; Ureshino, R.P.; Getachew, B.; Costa, S.L.; da Silva, V.D.A.; Tizabi, Y. Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease. Cells 2024, 13, 474.
Soares, É.N.; Costa, A.C.S.; Ferrolho, G.J.; Ureshino, R.P.; Getachew, B.; Costa, S.L.; da Silva, V.D.A.; Tizabi, Y. Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease. Cells2024, 13, 474.
Soares, É.N.; Costa, A.C.S.; Ferrolho, G.J.; Ureshino, R.P.; Getachew, B.; Costa, S.L.; da Silva, V.D.A.; Tizabi, Y. Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease. Cells 2024, 13, 474.
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by resting tremor, bradykinesia, rigidity, postural instability, that also includes non-motor symptoms such as mood dysregulation. Dopamine (DA) is the primary neurotransmitter involved in this disease, but cholinergic imbalance has also been implicated. Current intervention in PD is focused on replenishing central DA, which provides remarkable temporary symptomatic relief but does not address the neuronal losss and the progression of the disease. It has been well established that neuronal nicotinic cholinergic receptors (nAChRs) can regulate DA release and that nicotine itself may have neuroprotective effects. Recent studies have identified nAChRs in nonneuronal cell types including glial cells, where they may regulate inflammatory responses. Given the crucial role of neuroinflammation in dopaminergic degeneration, and involvement of microglia and astrocytes in this response, glial nAChRs may provide a novel therapeutic target in prevention and/or treatment of PD. In this review, following a brief discussion of PD, we focus on the role of glial cells and specifically their nAChRs in PD pathology and/or treatment.
Biology and Life Sciences, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.